Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Trial Profile

Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Ruxolitinib (Primary) ; Protein tyrosine kinase inhibitors
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Jul 2013 Status changed from not yet recruiting to recruiting as reported by M.D. Anderson Cancer Center.
    • 26 Jul 2013 New source identified and integrated (M.D. Anderson Cancer Center, 2012-0697).
    • 25 Jul 2013 Planned End Date changed from 1 Oct 2019 to 1 Jul 2019 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top